[Liver transplantation in tumors].
According to the European Liver Transplant Registry the percentage of patients selected to receive liver grafts for malignant liver disease decreased from 40% in 1983 to 23% currently. This development is due to disappointing results: 2-year survival rates of about 25-30% have been reported for malignant diseases compared to about 70% for benign diseases. Correlating the stage of the primary tumor and the survival time according to TNM-grading recent publications now show that the T1-3 and N-0 stage are clearly prognostic for long-term survival in contrast to a T-4 or N-1 stage which indicate a limited prognosis for about 90% of patients with HCC and Klatskin carcinoma during the first postoperative year.
Kremer
B
B
Chirurgische Universitätsklinik Hamburg-Eppendorf.
D002759:Adenoma, Bile Duct / Q000401:mortality / Q000601:surgery*; D001650:Bile Duct Neoplasms / Q000401:mortality / Q000601:surgery*; D006528:Carcinoma, Hepatocellular / Q000401:mortality / Q000601:surgery*; D005500:Follow-Up Studies; D006801:Humans; D008103:Liver Cirrhosis / Q000401:mortality / Q000601:surgery; D008113:Liver Neoplasms / Q000401:mortality / Q000601:surgery*; D016031:Liver Transplantation; D011183:Postoperative Complications / Q000401:mortality; D015996:Survival Rate
Lebertransplantation bei Tumoren.